Browsing Tag
Eplontersen
3 posts
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
AstraZeneca (AZN) shares fall as Wainua Phase III trial miss dents ATTR-CM growth hopes
Read how AstraZeneca’s Wainua trial miss reshapes AZN stock sentiment, ATTR-CM competition and its 2030 growth story after July 9.
AstraZeneca, Ionis Pharmaceuticals get FDA approval of Wainua for ATTRv-PN
In a major development for hereditary transthyretin-mediated amyloidosis (ATTRv-PN or hATTR-PN) patients, the US Food and Drug Administration…